Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
ATYR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.68 - $7.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)16.72M
Market Cap
$80.80M
Enterprise Value$389.05M
Total Cash (Recent Filing)$17.22M
Total Debt (Recent Filing)$12.68M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 06, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding97,986,630
10 Day Avg. Volume14,609,563
30 Day Avg. Volume16,720,421
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap4.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-5.62
Forecast
1Y Price Target
$8.10Price Target Upside864.29% Upside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical ImprovementsEfzofitimod has demonstrated promising efficacy and safety, and a positive Phase 3 outcome could support its first approval in pulmonary sarcoidosis.
Market PotentialEfzofitimod is the most advanced program for sarcoidosis, which is a sizable market with no approved targeted therapy and limited pipeline, suggesting a strong position for potential approval.
Stock Performance OutlookAnalyst reiterates an Outperform rating with a price target of $16, indicating confidence in the stock's potential performance.
Bears Say
Regulatory UncertaintyThere is doubt that the FDA will provide an immediate green light with the current dataset, despite positive quality of life outcomes in the stringent KSQ-L analysis with 5mg efzofitimod over placebo.
Stock Volatility RiskThe stock is currently trading around a cash value of $1.02 per share and could see further pullback if there is no clear decision on the fate of the programs soon.
Study Outcome ConcernsThe pivotal Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis.
aTyr Pharma News
ATYR FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was $0.68 and its highest was $7.29 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $80.80M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 29 days.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Aug 07, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.035.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.18.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 97,986,630 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went up 1.145%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in ATYR
aTyr Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.10 (864.29% Upside)
$8.10 (864.29% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.93%
12-Months-Change
Fundamentals
Return on Equity
-85.18%
Trailing 12-Months
Asset Growth
-4.16%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
ATYR Stock 12 Month Forecast
Average Price Target
$8.10
▲(864.29% Upside)
Technical Analysis
XBiotech
―
Repare Therapeutics
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
1.41% Insiders
28.53% Mutual Funds
13.78% Other Institutional Investors
47.76% Public Companies and Individual Investors
Options Prices
Currently, No data available
---